Clinical Trials Sponsored by BHV Pharma

Total 8967 results

Acerta Pharma BV

Active, not recruiting

An Open-label, Phase 2 Study of ACP-196 (Acalabrutinib) in Subjects With Mantle Cell Lymphoma

Mantle Cell Lymphoma (MCL)

Belgium, France, United Kingdom, United States, Italy, Poland, Netherlands, Australia, Czechia, Spain
Acerta Pharma BV

Completed

A Study to Evaluate the One-way Interaction of Calcium Carbonate, Omeprazole, or Rifampin on ACP-196

Healthy Participants

United States
Acerta Pharma BV

Completed

A Study to Evaluate the Effect of ACP-196 on the Heart Rate-corrected QT Interval in Healthy Adult Participants

Healthy Volunteers

United States
Acerta Pharma BV

Withdrawn

A Study of Acalabrutinib in Combination With Rituximab Versus Ibrutinib Versus Acalabrutinib in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Mantle Cell Lymphoma
Acerta Pharma BV

Active, not recruiting

Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States, Italy, Spain, United Kingdom, Belgium, Denmark, Hungary, Poland, Australia, Germany, Israel, Netherlands, Turkey, France, New Zealand
Acerta Pharma BV

Active, not recruiting

A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United Kingdom, Poland
Acerta Pharma BV

Completed

A Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics, Food Effects, and Drug-drug Interactions of ACP-196 in Healthy Participants

Healthy Participants

United States
Acerta Pharma BV

Terminated

A Study of Acalabrutinib and Vistusertib in Subjects With Relapsed/Refractory B-cell Malignancies

DLBCL | Richter Syndrome

United Kingdom, United States
Acerta Pharma BV

Completed

ACP-196 Versus Placebo in Subjects With Rheumatoid Arthritis on Background Methotrexate

Rheumatoid Arthritis

United States
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease Patients Not Requiring Dialysis (ALPS)

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Spain, Belarus, Bulgaria, Hungary, Poland, Romania, Russian Federation, Serbia, Ukraine, United Kingdom, Belgium, Georgia, Italy, Colombia, Dominican Republic, Estonia, Greece, Guatemala, Panama, Peru, South Africa, Turkey
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in End Stage Renal Disease (ESRD) Patients on Stable Dialysis (Pyrenees)

Anemia | End Stage Renal Disease (ESRD)

Bulgaria, Croatia, Czechia, Germany, Hungary, Poland, Russian Federation, Serbia, Spain, United Kingdom, Belgium, France, Georgia, Italy, Portugal, Romania, Slovakia
Astellas Pharma Europe B.V.
FibroGen

Completed

Roxadustat in the Treatment of Anemia in Chronic Kidney Disease (CKD) Patients, Not on Dialysis, in Comparison to Darbepoetin Alfa (Dolomites)

Anemia in Chronic Kidney Disease in Non-dialysis Patients

Austria, Belarus, Bulgaria, Croatia, Czechia, Finland, France, Georgia, Germany, Hungary, Ireland, Israel, Latvia, Montenegro, Netherlands, North Macedonia, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, Slovenia, Spain and more
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Dose-proportionality and Effects of FG-4592 in Healthy Young and Elderly Male and Female Subjects

Healthy Subjects | PK for FG-4592

Germany
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Investigate the Exposure and Safety and Tolerability of a Single Dose of FG-4592 in Subjects With Moderately Diminished Liver Function Compared to Those With Normal Liver Function

Hepatic Insufficiency | Healthy Subjects | PK of FG-4592

Bulgaria
Astellas Pharma Europe B.V.
FibroGen

Completed

A Phase 1 Study of Roxadustat in Subjects With Different Degrees of Renal Function

Impaired Renal Function | Normal Renal Function

Germany, United Kingdom
Astellas Pharma Europe B.V.
FibroGen

Completed

A Study to Evaluate the Effects of Multiple Doses of FG-4592 on the Exposure, Safety and Tolerability and Effect of Warfarin in Healthy Subjects

Healthy Subjects | Pharmacokinetics of FG-4592

Germany
Acerta Pharma BV
Acerta Pharma, LLC

Completed

An Open-Label, Phase 1b Study of Acalabrutinib With and Without Dexamethasone in Subjects With Multiple Myeloma

Multiple Myeloma (MM)

United States, United Kingdom
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer

Metastatic Castration-Resistant Prostate Cancer

Belgium, France, Germany, Spain, United Kingdom
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Evaluate How a Drug That Alters Liver Enzymes (Rifampin) Affects the Metabolism of Enzalutamide in Men

Healthy Subjects | Drug-Drug Interaction (DDI) | Pharmacokinetics of Enzalutamide

Germany
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Investigate the Effect of Severely Diminished Liver Function on the Metabolism, Safety, and Tolerability of a Single Oral Dose of Enzalutamide in Men

Severe Hepatic Impairment | Normal Hepatic Function

Bulgaria
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Explore the Routes of Elimination of MDV3100

Healthy Subjects | Pharmacokinetics of MDV3100

Netherlands
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants (Himalayas)

Anemia in Incident Dialysis Patients

Russian Federation, Bulgaria, Thailand, United States, Argentina, Chile, Colombia, Korea, Republic of, Latvia, Malaysia, Mexico, Poland, Romania, Taiwan, Ukraine
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis

CKD Anemia

United States, Australia, Thailand, Korea, Republic of, Malaysia, Mexico, Taiwan, New Zealand, Argentina, Chile, Colombia, Hong Kong, Peru, Philippines, Puerto Rico, Singapore
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL (AMPLIFY)

Chronic Lymphocytic Leukemia

United States, Spain, Canada, Italy, Taiwan, Russian Federation, Turkey, Germany, Korea, Republic of, Brazil, Hungary, Poland, China, Sweden, Bulgaria, Israel, United Kingdom, Australia, Saudi Arabia, Austria, France, Czechia, South... and more
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Lymphoma, Mantle Cell

United States, France, Italy, Taiwan, Mexico, Russian Federation, Vietnam, Belgium, Canada, Brazil, Hungary, Japan, Poland, China, Spain, Germany, Australia, Czechia, Korea, Republic of, Israel, Romania, Ukraine, Argentina, Peru, New Zealand and more
Acerta Pharma BV
AstraZeneca

Terminated

Acalabrutinib Study With Best Supportive Care in Participants Hospitalized With COVID-19

COVID-19

Brazil
AstraZeneca
Acerta Pharma BV

Completed

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (CALAVI)

COVID-19

Italy, Turkey, Brazil, Japan, South Africa, Germany, Poland, Russian Federation, India, Peru, France, Argentina, Chile, Mexico
AstraZeneca
Acerta Pharma BV

Completed

Acalabrutinib Study With Best Supportive Care Versus Best Supportive Care in Subjects Hospitalized With COVID-19. (CALAVI US)

COVID-19

United States
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Monitor the Safety of Enzalutamide in Patients With Progressive Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Prostate Cancer | Castration-Resistant Prostate Cancer

Russian Federation, Georgia
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Evaluate How Daily Dosing With Enzalutamide Affects the Metabolism of Caffeine and Dextromethorphan in Men With Prostate Cancer

Prostate Cancer | Pharmacokinetics of Dextromethorphan | Pharmacokinetics of Caffeine

Moldova, Republic of
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

Hepatic Impairment Study With MDV3100 in Subjects With Mild and Moderate Hepatic Impairment Compared to a Healthy Control Group

Kidney Diseases | Healthy Subjects | Pharmacokinetics of MDV3100

Moldova, Republic of
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients

Prostate Cancer | Pharmacokinetics of Enzalutamide

United States
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

Drug-drug Interaction Study With MDV3100 (ASP9785) and Gemfibrozil and Itraconazole

Healthy Subjects | Pharmacokinetics | Drug-Drug Interaction

France
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

A Study to Compare Capsule and Tablet Forms of MDV3100 (Enzalutamide) After Administration of a Single Set Dose Under Fasted Conditions in Healthy Male Subjects

Healthy Subjects | Relative Bioavailability | Castration Resistant Prostate Cancer (CRPC) | MDV3100

Germany
Astellas Pharma Europe B.V.
Medivation, Inc.

Completed

Drug-drug Interaction Study With MDV3100 and a Cocktail of Substrates

Castration Resistant Prostate Cancer (CRPC) | Pharmacokinetics of MDV3100

South Africa
Acerta Pharma BV
AstraZeneca

Completed

Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (PRISM)

Diffuse Large B Cell Lymphoma | NHL | Non-hodgkin's Lymphoma | DLBCL

United States, United Kingdom
AstraZeneca
Acerta Pharma BV

Completed

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

Infectious Disease

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies

Multiple Myeloma | Non-Hodgkins Lymphoma | B-All

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

Study of Acalabrutinib Alone or in Combination Therapy in Subjects With B-cell Non-Hodgkin Lymphoma

Non Hodgkin Lymphoma

United States, Canada, Italy
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)

Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, Canada, Taiwan, Germany, Korea, Republic of, Brazil, Japan, Russian Federation, Poland, China, Israel, Belgium, Australia, Austria, Czechia, Portugal, Mexico, Turkey, India, Ukraine
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL

Mantle Cell Lymphoma (MCL)

United States, Poland, Italy
Amphera BV
TMC Pharma

Completed

DENdritic Cell Immunotherapy for Mesothelioma (DENIM)

Mesothelioma

Netherlands, France, United Kingdom, Belgium, Italy
Acerta Pharma BV
AstraZeneca

Completed

Investigate the Influence of Severe Hepatic Impairment on the Pharmacokinetics of Acalabrutinib and Its Metabolite

Hepatic Insufficiency | Healthy Subjects | Hepatic Impairment

United States
FibroGen
AstraZeneca; Astellas Pharma Europe B.V.

Completed

Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis

CKD Anemia in Stable Dialysis Patients

United States, Puerto Rico
Astellas Pharma Europe B.V.
Cubist Pharmaceuticals LLC

Completed

A Study to Assess the Effects of Multiple Doses of Fidaxomicin on a Single Dose of Rosuvastatin in Healthy Male Subjects

Healthy Subjects | Drug-Drug Interaction (DDI) | Intestinal Absorption | Pharmacokinetics of Rosuvastatin | Pharmacokinetics of Fidaxomicin

Germany
Astellas Pharma Europe B.V.
Veeda Clinical Research

Completed

Observational, Non-interventional, Non Comparative Real Life Data Collection of Depo-Eligard® 7.5 mg, 22.5 mg and 45 mg in Male Prostate Cancer Patients (TREMODI)

Prostate Cancer

Belgium
Astellas Pharma Europe B.V.
Veeda Clinical Research

Completed

Treatment of Symptoms in Male Patients With Lower Urinary Tract Symptoms (LUTS) Predominant Storage Symptoms (Overactive Bladder Syndrome) (VENICE)

Lower Urinary Tract Predominant Storage Symptoms

Belgium
Analgesic Solutions
Pfizer; Astellas Pharma Europe B.V.

Unknown

Evaluation of the Impact of Training on Outcome Measures in Subjects With Painful Diabetic Neuropathy

Diabetes Mellitus | Painful Distal Symmetric Sensorimotor Polyneuropathy

United States
Astellas Pharma Europe B.V.
Merck Sharp & Dohme LLC

Completed

A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD) (SUNSHINE)

Clostridium Difficile-associated Diarrhea (CDAD)

United States, Belgium, Italy, Canada, France, Germany, Hungary, Poland, Romania, Spain
BHR Pharma, LLC
Q2 Solutions; H2O Clinical LLC

Terminated

Maintaining Suppression of Testosterone With Transdermal Estradiol Gel (MASTERS)

Cancer of the Prostate

United States

Clinical Trials Sponsored by BHV Pharma

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ghana

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations